Elevated IL-4 Receptor in Carcinoma: A Target for Immunotherapy
Author Information
Author(s): B. Al Jabaari, H.M. Ladyman, M. Larche, G.B. Sivolapenk, A.A. Epenetos, M.A. Ritter
Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
Is elevated expression of the interleukin 4 receptor in carcinoma a viable target for immunotherapy?
Conclusion
The study suggests that the IL-4 receptor is expressed at high levels in epithelial tumors, indicating its potential as a target for immunotherapy.
Supporting Evidence
- All 20 epithelial tumors tested were found to be strongly positive for the IL-4 receptor.
- The corresponding normal tissues showed either weak or no expression of the IL-4 receptor.
- Monoclonal antibody MR6 may be useful for both diagnosis and therapy of epithelial cancers.
Takeaway
This study found that a specific receptor is much more common in cancer cells than in normal cells, which could help doctors find and treat cancer better.
Methodology
The study analyzed tissue samples from various tumors and normal tissues using immunohistochemical methods and Western blotting.
Limitations
The study's findings are based on a limited number of samples, and further research is needed to confirm the results across a larger population.
Want to read the original?
Access the complete publication on the publisher's website